| Names | |
|---|---|
| IUPAC name
Methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-[(E)-3,4-dimethylpent-2-enoyl]oxy-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate | |
| Other names
Bruceantine | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID |
|
| UNII | |
| |
| |
| Properties | |
| C28H36O11 | |
| Molar mass | 548.585 g·mol−1 |
| Melting point | 225–226 °C (437–439 °F; 498–499 K) |
| Hazards | |
| Lethal dose or concentration (LD, LC): | |
LD50 (median dose) |
mouse (male, IV) 1.95 mg/kg mouse (female, IV) 2.58 mg/kg |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Bruceantin is a chemical compound that was first isolated from the plant Brucea antidysenterica in 1973. Chemically, it is classified as a secotriterpenoid and a quassinoid.
Bucreantin has attracted interest as a potential antitumor drug because of its antineoplastic activity. It inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis. Bruceantin also has antibiotic, antiamoebic, and antimalarial activity.
Phase I and II clinical trials were conducted for the treatment of metastatic breast cancer and melanoma, but tumor regression was not observed and clinical development was terminated.